Pre-Descemet’s endothelial keratoplasty (PDEK)

AsianOphthalmology Alliance logo Pre-Descemet’s endothelial keratoplasty (PDEK)

Incorporation of Dua’s layer for creation of Type-1 bubble in Pre-Descemet’s endothelial keratoplasty. Check out this new publication in BJO- with Dr. HarminderSingh Dua

Amar Agarwal1, Harminder S Dua2, Priya Narang3, Dhivya A Kumar1, Ashvin Agarwal1, Soosan Jacob1, Athiya Agarwal1, Ankur Gupta2

To read about it Click Here

British Journal of Ophthalmology (144)



Office-based vitrectomy: proceed with caution

Office-based vitrectomy: proceed with caution In a pro/con session during AAO 2013 Retina meeting, Thomas M. Aaberg Jr, MD, and Steven T. Charles, MD, argued the merits of office-based vitrectomy. Rationale for. Primary reasons for making the switch include cost, convenience, and control, Dr. Aaberg said. Proper patient and case selection is essential, he cautioned.…

more

Ex-Press shunt, trabeculectomy yield similar outcomes

Ex-Press shunt, trabeculectomy yield similar outcomes This multicenter, prospective, randomized study compared outcomes with trabeculectomy (61 eyes) and the Ex-Press glaucoma filtration implant (59 eyes) placed under a partial-thickness scleral flap. At two years follow-up, outcomes were similar in terms of mean IOPs, medication use, and surgical success. Although the Ex-Press group returned to baseline… more

Dr Quresh Maskati takes over as President of AIOS

Dr Quresh Maskati takes over as President of AIOS A big & hearty congratulations to our own Dr Quresh on his installation as President of the All India Ophthalmological Society (AIOS) during the 2014 Annual Conference of the society held in the city of Agra in India. The society is safe and in competent hands… more

Risk factors for acute postoperative intraocular pressure elevation after phacoemulsification in glaucoma patients

Risk factors for acute postoperative intraocular pressure elevation after phacoemulsification in glaucoma patients Author(s): Slabaugh M, Bojikian K, Moore D, Chen P Treatments discussed: acetazolamide PURPOSE To evaluate the risk factors for and frequency of an acute intraocular pressure (IOP) elevation (spike) after phacoemulsification in patients with glaucoma. (625)

more

FDA accepts Regeneron’s Eylea sBLA for standard review

AsianOphthalmology Alliance logo FDA accepts Regeneron’s Eylea sBLA for standard review

The supplemental Biologics License Application (sBLA) on Eylea intravitreal injection (aflibercept, Regeneron, Tarrytown, N.Y.) for the treatment of diabetic macular edema (DME) has been accepted by the Food and Drug Administration, with a targeted Prescription Drug User Fee Act date of August 18, 2014.

The submission was based on positive data from Regeneron’s VIVID and VISTA studies. Eylea is currently approved in the U.S. for neovascular age-related macular degeneration and for macular edema following central retinal vein occlusion.

EyeWorld Weekly Update (702)

Complications of Glued IOL : Dr Priya Narang

Healio_OSN: BLOG: Complications of glued IOL, by Priya Narang, MS. Read it here: http://ow.ly/rRsOX (374)

17th Annual Conference Of Punjab Ophthalmological Society

AsianOphthalmology Alliance logo 17th Annual Conference Of Punjab Ophthalmological Society to be held at Jalandhar, Punjab, India at Grand Lilly Resorts from Dec 20 to Dec 22 2013. To download the program brochure please click

POS-2013-CONFERENCE BROCHURE .(3.5MB PDF) (356)

Intracameral bevacizumab as an adjunct to trabeculectomy

AsianOphthalmology Alliance logo Intracameral bevacizumab as an adjunct to trabeculectomy

Author(s): Vandewalle E, Abegão Pinto L, Van Bergen T, Spielberg L, Fieuws S, Moons L, Spileers W, Zeyen T, Stalmans I
Treatments discussed: bevacizumab

AIMS To investigate the efficacy and safety of a single intracameral bevacizumab injection to improve the outcome of trabeculectomy.

METHODS A 12-month, prospective, randomised, double-masked, placebo-controlled trial. Patients with medically uncontrolled open-angle glaucoma scheduled for a primary trabeculectomy were recruited and randomised to receive 50 µL of either bevacizumab (1.25 mg) or placebo (balanced salt solution) peroperatively. Absolute success was defined as intraocular pressure (IOP) ≤18 mm Hg and>5 mm Hg with at least 30% reduction from baseline and no loss of light perception. (more…) (375)

Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants?

AsianOphthalmology Alliance logo Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants?

Author(s): Kiryazov K, Stefova M, Iotova V
Treatments discussed: brimonidine, brinzolamide, timolol

Topical ocular medications have been widely prescribed and successfully used in children for the management of different ophthalmic disorders. We present 2 infants admitted to our pediatric intensive care unit who developed altered state of consciousness, hypotonia, hypothermia, bradycardia, and apnea after instillation of ophthalmic drops. The second infant also had (more…) (831)

Next Page »